228 related articles for article (PubMed ID: 21481442)
1. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.
Sheffer AL; Campion M; Levy RJ; Li HH; Horn PT; Pullman WE
J Allergy Clin Immunol; 2011 Jul; 128(1):153-159.e4. PubMed ID: 21481442
[TBL] [Abstract][Full Text] [Related]
2. Ecallantide for the treatment of acute attacks in hereditary angioedema.
Cicardi M; Levy RJ; McNeil DL; Li HH; Sheffer AL; Campion M; Horn PT; Pullman WE
N Engl J Med; 2010 Aug; 363(6):523-31. PubMed ID: 20818887
[TBL] [Abstract][Full Text] [Related]
3. Response time for ecallantide treatment of acute hereditary angioedema attacks.
Riedl M; Campion M; Horn PT; Pullman WE
Ann Allergy Asthma Immunol; 2010 Dec; 105(6):430-436.e2. PubMed ID: 21130380
[TBL] [Abstract][Full Text] [Related]
4. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.
Levy RJ; Lumry WR; McNeil DL; Li HH; Campion M; Horn PT; Pullman WE
Ann Allergy Asthma Immunol; 2010 Jun; 104(6):523-9. PubMed ID: 20568386
[TBL] [Abstract][Full Text] [Related]
5. Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.
Stolz LE; Sheffer AL
Expert Rev Clin Immunol; 2012 Jan; 8(1):25-32. PubMed ID: 22149337
[TBL] [Abstract][Full Text] [Related]
6. Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.
Bernstein JA; Shea EP; Koester J; Iarrobino R; Pullman WE
Allergy; 2012 Sep; 67(9):1173-80. PubMed ID: 22765833
[TBL] [Abstract][Full Text] [Related]
7. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.
Schneider L; Lumry W; Vegh A; Williams AH; Schmalbach T
J Allergy Clin Immunol; 2007 Aug; 120(2):416-22. PubMed ID: 17559913
[TBL] [Abstract][Full Text] [Related]
8. Use of ecallantide in pediatric hereditary angioedema.
MacGinnitie AJ; Davis-Lorton M; Stolz LE; Tachdjian R
Pediatrics; 2013 Aug; 132(2):e490-7. PubMed ID: 23878046
[TBL] [Abstract][Full Text] [Related]
9. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.
MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
Allergy Asthma Proc; 2012; 33(2):178-85. PubMed ID: 22525395
[TBL] [Abstract][Full Text] [Related]
10. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.
Banta E; Horn P; Craig TJ
Allergy Asthma Proc; 2011; 32(4):319-24. PubMed ID: 21781409
[TBL] [Abstract][Full Text] [Related]
11. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide.
Li HH; Campion M; Craig TJ; Soteres DF; Riedl M; Lumry WR; MacGinnitie AJ; Shea EP; Bernstein JA
Ann Allergy Asthma Immunol; 2013 Mar; 110(3):168-72. PubMed ID: 23548526
[TBL] [Abstract][Full Text] [Related]
12. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.
Sheffer AL; MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
Ann Allergy Asthma Immunol; 2013 Mar; 110(3):184-188.e2. PubMed ID: 23548529
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.
Lumry WR; Bernstein JA; Li HH; MacGinnitie AJ; Riedl M; Soteres DF; Craig TJ; Campion M; Iarrobino R; Stolz LE; Pullman WE
Allergy Asthma Proc; 2013; 34(2):155-61. PubMed ID: 23484891
[TBL] [Abstract][Full Text] [Related]
14. Hereditary angioedema: new hopes for an orphan disease.
Reshef A; Leibovich I; Goren A
Isr Med Assoc J; 2008 Dec; 10(12):850-5. PubMed ID: 19160940
[TBL] [Abstract][Full Text] [Related]
15. Management and prevention of hereditary angioedema attacks.
Lumry WR
Am J Manag Care; 2013 Jun; 19(7 Suppl):s111-8. PubMed ID: 23844783
[TBL] [Abstract][Full Text] [Related]
16. Successful resolution of bowel obstruction in a patient with hereditary angioedema.
Zingale LC; Zanichelli A; Deliliers DL; Rondonotti E; De Franchis R; Cicardi M
Eur J Gastroenterol Hepatol; 2008 Jun; 20(6):583-7. PubMed ID: 18467921
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.
Craig TJ; Levy RJ; Wasserman RL; Bewtra AK; Hurewitz D; Obtułowicz K; Reshef A; Ritchie B; Moldovan D; Shirov T; Grivcheva-Panovska V; Kiessling PC; Keinecke HO; Bernstein JA
J Allergy Clin Immunol; 2009 Oct; 124(4):801-8. PubMed ID: 19767078
[TBL] [Abstract][Full Text] [Related]
18. Hereditary angioedema: management of laryngeal attacks.
Christiansen SC; Zuraw BL
Am J Rhinol Allergy; 2011; 25(6):379-82. PubMed ID: 22185739
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks.
Wasserman RL; Levy RJ; Bewtra AK; Hurewitz D; Craig TJ; Kiessling PC; Keinecke HO; Bernstein JA
Ann Allergy Asthma Immunol; 2011 Jan; 106(1):62-8. PubMed ID: 21195947
[TBL] [Abstract][Full Text] [Related]
20. Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema.
Stolz LE; Horn PT
Drugs Today (Barc); 2010 Aug; 46(8):547-55. PubMed ID: 20830315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
